Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

This study has been completed.
Information provided by:
Sangamo Biosciences Identifier:
First received: November 11, 2005
Last updated: September 2, 2016
Last verified: September 2016